Celularity Inc. (CELUW)

NASDAQ: CELUW · Real-Time Price · USD · Warrants
0.0391
+0.0016 (4.27%)
Apr 25, 2025, 4:00 PM EDT - Market closed
4.27%
Market Cap 35.32M
Revenue (ttm) 48.20M
Net Income (ttm) -35.05M
Shares Out 22.48M
EPS (ttm) -1.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 67,931
Open 0.0376
Previous Close 0.0375
Day's Range 0.0376 - 0.0391
52-Week Range 0.0362 - 0.0399
Beta 0.58
Analysts n/a
Price Target n/a
Earnings Date Mar 31, 2025

About CELUW

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 120
Stock Exchange NASDAQ
Ticker Symbol CELUW
Full Company Profile

Financial Performance

News

There is no news available yet.